Table 2: Characteristics of chemotherapy regimens incorporated into the model.

RegimenMean dose per cycleAdmissions/outpatient clinic attendances per cycle

CYVADIC600 mg/m2 cyclophosphamide4 outpatient clinic attendances
1 mg/m2 vincristine
30 mg/m2 doxorubicin
250 mg/m2 dacarbazine
Docetaxel100 mg/m2 docetaxel1 outpatient clinic attendance
Doxorubicin75 mg/m2 doxorubicin1 outpatient clinic attendance
Doxorubicin/ifosfamide66 mg/m2 doxorubicin3-4-day admission
8.5 g/m2 ifosfamide
Ifosfamide12.5 g/m2 ifosfamide4-day admission or 2 outpatient clinic attendances
Ifosfamide/epirubicin100 mg/m2 epirubicin3-day admission
5 g/m2 ifosfamide
Gemcitabine1,000 mg/m2 gemcitabine2 outpatient clinic attendances
Gemcitabine/dacarbazine1,766 mg/m2 gemcitabine2 outpatient clinic attendances
700 mg/m2 dacarbazine
Gemcitabine/docetaxel1,000 mg/m2 gemcitabine 2 outpatient clinic attendances
75 mg/m2 docetaxel
Gemcitabine/paclitaxel1,000 mg/m2 gemcitabine2 outpatient clinic attendances
125 mg/m2 paclitaxel
Gemcitabine/vinorelbine1,250 mg/m2 gemcitabine2 outpatient clinic attendances
25 mg/m2 vinorelbine
Liposomal doxorubicin50 mg/m2 doxorubicin1 outpatient clinic attendance
Trabectedin1.3 mg/m2 trabectedin2-day admission
Trofosfamide200 mg/m2 trofosfamide Oral administration over ~10 days, no hospital attendance
Trofosfamide/etoposide150 mg/m2 trofosfamideOral administration over ~10 days, no hospital attendance
25 mg/m2 etoposide

CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.